This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
What Is the Role of Pneumococcal Vaccination in Renal Diseases?
Burden of Chronic Renal Diseases
CKDs are defined as abnormalities of kidney structure or function, present for >3 months, with implications for health and are categorised based on the cause, GFR category and albuminuria.1 A population screening of 4712 subjects in New Delhi2 suggested that there are approximately 7.85 million patients with CRF in India and etiologically diabetes accounted for 41% of all causes. Another prospective study in 48 centres distributed all over India suggested the prevalence of CRF to be 0.8% in India.3 Diabetic nephropathy was found to be the most common cause of CKD in a cross-sectional study using the Indian CKD registry and about 48% of cases were in Stage V at presentation.4
Infectious Complications in Chronic Renal Diseases
Regardless of the primary cause for the development of CKD, patient outcomes after the development of infections were 3 to 4 times worse as compared with the non-CKD population. Compared with the non-CKD population, the rates of pneumonia are 3 times greater in the CKD population and 5 times greater in the dialysis population.5 The annual percentage of mortality secondary to sepsis is approximately 100- to 300-fold higher in patients with dialysis.6 According to the Medicare claims in patients initiating dialysis in the US between 1996 and 2001, 1 in 5 patients was diagnosed with pneumonia in the 1-year period following the inception of dialysis therapy, and the cumulative survival probability was 0.51 at 1 year after the first occurrence of pneumonia.7 In a population-based retrospective cohort study from Taiwan, the incidence rate ratio of ESRD was 23% higher in individuals with pneumococcal pneumonia than in those without pneumococcal pneumonia (5.26 vs. 3.10 per 1000 person-years).8 The incidence rate of IPD in organ transplant population is 12.7 times more than the general population.9
CKD, chronic kidney disease; CRF, chronic renal failure; ESRD, end-stage renal disease; GFR, glomerular filtration rate; IPD, invasive pneumococcal disease.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.